Drug Profile
Budesonide inhalation - MAP Pharmaceuticals
Alternative Names: MAP 0010; UDB; Unit dose budesonideLatest Information Update: 19 Dec 2021
Price :
$50
*
At a glance
- Originator MAP Pharmaceuticals
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Asthma
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 01 Mar 2013 MAP Pharmaceuticals has been acquired by Allergan
- 25 May 2012 Budesonide inhalation - MAP is available for licensing in World as of 25 May 2012. http://www.mappharma.com/